Prabhu Manivannan

Dr. Prabhu Manivannan

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2014 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
SVS. Venkatesan
S. Venkatesan
APAbhishek Purohit
Abhishek Purohit
MAMukul Aggarwal
Mukul Aggarwal
PMPrabhu Manivannan
Prabhu Manivannan
STSeema Tyagi
Seema Tyagi
RSRenu Saxena
Renu Saxena

17 April 2023 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
MSMithraa Devi Sekar
Mithraa Devi Sekar
MRManasa Raj
Manasa Raj
PMPrabhu Manivannan
Prabhu Manivannan
The role of hematopathologists in the diagnosis of acute leukemia (AL) starts with the morphological examination of either peripheral blood smear or bone marrow. The morphological hallmark for the myeloblast includes “Auer rods” and “Phi bodies.” The addition of cytochemical stains such as myeloperoxidase, Sudan Black B, periodic acid-Schiff stain, nonspecific esterase, and Perls' stain acts as an important adjunct to the morphological classification in the resource-constrained settings. The recent World Health Organization classification still endorses the utility of morphology which requires the presence of either ≥ 20% lymphoblasts or myeloblasts/or its equivalents (monoblasts, promonocytes, or megakaryoblasts) and integrates it with the clinical features, immunophenotyping (IP), and molecular genetics for making the diagnosis of AL. Morphology can give clue to the specific diagnosis of acute myeloid leukemia (AML) with t(8:21), t(15:17), t(16:16), or inv(16) and this diagnosis can be made irrespective of blasts count if such translocations are demonstrated by molecular tests. There are some interesting findings such as blasts with “hand-mirror” morphology, nuclear cleavage, prominent cytoplasmic vacuoles, pseudo-Chediak-Higashi granules, cup-like nucleus, and other dysplastic features helping in differentiating lymphoid and myeloid leukemias. Transient abnormal myelopoiesis in Down syndrome and hypoplastic AL can be picked up on morphological examination. Bone marrow biopsy would be greatly beneficial and complementary to aspirate smears and is required for diagnosing exact cellularity, topography of cells, dyspoiesis, myelonecrosis, gelatinous marrow transformation, myelofibrosis, and IP can be performed using immunohistochemistry. Morphological examination in AL is not only helpful for diagnosis but also useful for predicting the prognosis in posttherapy cases, AML with myelodysplasia-related changes, therapy-related myeloid neoplasms, and mixed phenotype AL. Hematogones, blastoid mantle cell lymphoma, high grade B cell lymphoid with blastoid morphology, Burkitt leukemia, prolymphocytes in prolymphocytic leukemia, hairy cell leukemia variant, plasmablasts especially in plasmablastic leukemia, or plasma cell leukemia can mimic AL and IP is useful in these situations. Hence, morphology should be considered as a kind of “gold-standard” starting point for the analysis of AL cases. Morphological examination cannot be replaced and advanced tests cannot be used as surrogate for morphology.

5 November 2019 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
PMPrabhu Manivannan
Prabhu Manivannan
STSeema Tyagi
Seema Tyagi
HPHara Prasad Pati
Hara Prasad Pati
RSRenu Saxena
Renu Saxena

29 June 2024 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
MDMallesh Dhanush
Mallesh Dhanush
KVKolar Vishwanath Vinod
Kolar Vishwanath Vinod
PMPrabhu Manivannan
Prabhu Manivannan
PAPrashant Adole
Prashant Adole
DGDhanajayan Govindan
Dhanajayan Govindan

1 January 2021 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Open access
PDF file
RKRakhee Kar
Rakhee Kar
TDTuphan Kanti Dolai
Tuphan Kanti Dolai
PSPrakash Singh Shekhawat
Prakash Singh Shekhawat
PMPankaj Malhotra
Pankaj Malhotra
ASAvinash Singh
Avinash Singh
RJRabindra Kumar Jena
Rabindra Kumar Jena
The SARS-CoV-2 (COVID-19) pandemic is a worldwide public health emergency with widespread impact on health care delivery. Unforeseen challenges have been noted during administration of usual haematology care in these unusual COVID-19 times. Medical services have been overstretched and frontline health workers have borne the brunt of COVID-19 pandemic. Movement restrictions during lockdown prevented large sections of population from accessing health care, blood banks from holding blood drives, and disrupted delivery of diagnostic hematology services. The disruption in hematology care due to COVID-19 pandemic in India has been disproportionately higher compared to other subspecialities as hematology practice in India remains restricted to major cities. In this review we chronicle the challenges encountered in caring for hematology patients during the COVID-19 pandemic in India and put forth recommendations for minimizing their impact on provision of hematology care with special emphasis on hematology practice in lower and middle income countries (LMICs).